Galmed Pharmaceuticals announced a collaboration with Tel Aviv University to develop Aramchol, a brain-penetrant SCD1 inhibitor, as a novel treatment for metastatic brain cancer linked to p53 mutations. This partnership leverages recent research showing that p53 inactivation drives brain metastasis through SCD1 upregulation, making Aramchol a promising therapy for these aggressive tumors. The collaboration aims to validate Aramchol's effectiveness using advanced preclinical models, supporting its potential expansion into oncological indications beyond liver disease. This development could offer new hope for patients with brain metastases, a condition with very poor survival rates under current treatments.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
UniFirst Corporation has been recognized on Selling Power's 60 Best Companies to Sell For list for the 23rd consecutive year, highlighting its strong sales culture and support for sales professionals. The list evaluates companies on compensation, tra...
Traders on Polymarket have significantly reduced their bets on a Tesla-SpaceX merger announcement this year, with the chance of a deal by September 30 now at 11%, down 28 points, and by December 31 at 24%, down 19 points. This decline contrasts with ...
Eli Lilly announced it will acquire psychedelic drugmaker AtaiBeckley for $2.8 billion upfront, gaining access to experimental drugs targeting mental health conditions like treatment-resistant depression. AtaiBeckley's lead drug, a DMT-based nasal sp...
Brazil Potash Corp. disclosed a procedural filing by the Brazilian Federal Public Defender’s Office seeking to suspend activities at its Autazes potash project. The filing challenges prior favorable court decisions but does not introduce new facts or...
